ANKRA Double Nickase Plasmid (h): sc-417372-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ANKRA Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- ANKRA Double Nickase Plasmid (h) and ANKRA Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting ANKRA2. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ANKRA Antibody (A26): sc-101005
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ANKRA Double Nickase Plasmid (h) | sc-417372-NIC | 20 µg | $410.00 |
ANKRA2 encodes ANKRA, an ankyrin repeat–containing protein implicated in protein–protein interaction networks that modulate transcriptional control and signal-dependent cellular responses. Through its ankyrin motifs, ANKRA is positioned to influence the assembly of regulatory complexes that impact chromatin-associated processes, cell cycle progression, and differentiation programs. Expression and functional perturbation of ankyrin repeat proteins, including ANKRA, have been investigated in the context of altered gene regulatory states observed in cancer and other disorders characterized by disrupted proliferation and cell fate control. ANKRA2 therefore serves as a useful target for dissecting regulatory circuitry and pathway crosstalk in human cellular models.
ANKRA Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the ANKRA2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within ANKRA2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt ANKRA2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of ANKRA2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.